https://pmc.ncbi.nlm.nih.gov/articles/PMC9458364/
Nimotuzumab in the Treatment of Inoperable Esophageal Tumors of Epithelial Origin - PMC
Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor. It was approved in Cuba for the indication of inoperable...
in thetreatment
https://hsrc.himmelfarb.gwu.edu/smhs_neuro_facpubs/150/
"Phase 2 study of safety and efficacy of nimotuzumab in pediatric patie" by Ute Bartels, Johannes...
By Ute Bartels, Johannes Wolff, Lia Gore, et al., Published on 11/01/14
https://adisinsight.springer.com/trials/700384867?error=cookies_not_supported&code=e4c71418-4e26-4d91-bd97-79a3a045222d
A Prospective, Phase Ib/II Study of Nimotuzumab Combined With Adebrelimab and Chemotherapy for the...
This is a prospective, single-arm, Phase Ib/II clinical study to evaluate the safety and efficacy of nimotuzumab combined with adebrelimab and chemotherapy in
https://adisinsight.springer.com/drugsafety/803294252?error=cookies_not_supported&code=1e040dc4-84fa-483c-ac6a-ba240898c004
Nimotuzumab - AdisInsight
In a retrospective study of 50 patients, two patients [ages and sexes not stated] were described, of which one patient developed anaemia and the second patient
adisinsight